KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Inventory (2023 - 2025)

Biocryst Pharmaceuticals' Inventory history spans 6 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Inventory fell 33.25% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $5.4 million, down 33.25%, while the annual FY2025 figure was $5.4 million, 33.25% down from the prior year.
  • Inventory reached $5.4 million in Q4 2025 per BCRX's latest filing, up from $5.2 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $29.8 million in Q1 2024 to a low of $4.4 million in Q2 2024.
  • Average Inventory over 3 years is $15.4 million, with a median of $7.8 million recorded in 2024.
  • Peak YoY movement for Inventory: crashed 83.54% in 2024, then grew 13.35% in 2025.
  • A 3-year view of Inventory shows it stood at $28.7 million in 2023, then plummeted by 71.81% to $8.1 million in 2024, then plummeted by 33.25% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Inventory are $5.4 million (Q4 2025), $5.2 million (Q3 2025), and $5.0 million (Q2 2025).